Cannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder

Abstract

ImportanceCannabis use is increasing worldwide and is suspected to be associated with increased risk of psychiatric disorders; however, the association with affective disorders has been insufficiently studied.ObjectiveTo examine whether cannabis use disorder (CUD) is associated with an increased risk of psychotic and nonpsychotic unipolar depression and bipolar disorder and to compare associations of CUD with psychotic and nonpsychotic subtypes of these diagnoses.Design, Setting, and ParticipantsThis prospective, population-based cohort study using Danish nationwide registers included all individuals born in Denmark before December 31, 2005, who were alive, aged at least 16 years, and living in Denmark between January 1, 1995, and December 31, 2021.ExposureRegister-based diagnosis of CUD.Main Outcome and MeasuresThe main outcome was register-based diagnosis of psychotic or nonpsychotic unipolar depression or bipolar disorder. Associations between CUD and subsequent affective disorders were estimated as hazard ratios (HRs) using Cox proportional hazards regression with time-varying information on CUD, adjusting for sex; alcohol use disorder; substance use disorder; having been born in Denmark; calendar year; parental educational level (highest attained); parental cannabis, alcohol, or substance use disorders; and parental affective disorders.ResultsA total of 6 651 765 individuals (50.3% female) were followed up for 119 526 786 person-years. Cannabis use disorder was associated with an increased risk of unipolar depression (HR, 1.84; 95% CI, 1.78-1.90), psychotic unipolar depression (HR, 1.97; 95% CI, 1.73-2.25), and nonpsychotic unipolar depression (HR, 1.83; 95% CI, 1.77-1.89). Cannabis use was associated with an increased risk of bipolar disorder in men (HR, 2.96; 95% CI, 2.73-3.21) and women (HR, 2.54; 95% CI, 2.31-2.80), psychotic bipolar disorder (HR, 4.05; 95% CI, 3.52-4.65), and nonpsychotic bipolar disorder in men (HR, 2.96; 95% CI, 2.73-3.21) and women (HR, 2.60; 95% CI, 2.36-2.85). Cannabis use disorder was associated with higher risk for psychotic than nonpsychotic subtypes of bipolar disorder (relative HR, 1.48; 95% CI, 1.21-1.81) but not unipolar depression (relative HR, 1.08; 95% CI, 0.92-1.27).Conclusions and RelevanceThis population-based cohort study found that CUD was associated with an increased risk of psychotic and nonpsychotic bipolar disorder and unipolar depression. These findings may inform policies regarding the legal status and control of cannabis use.

Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?

“…Nonetheless, attention should be given to possible associations between cannabis use and cardiovascular events 27 and severe psychiatric illness. 18 Several limitations of this study should be acknowledged. First, there may have been self-report bias, which was mitigated by using validated questionnaires and maintaining patient anonymity from their physicians.…”

Cannabis Science and Therapeutics: An Overview for Clinicians

“…54 In humans, phytocannabinoids may be used to manage depressive symptoms; however, individuals with cannabis use disorder are at greater risk for developing mood disorders such as unipolar and bipolar depression. 55 Some of the most compelling data came from clinical trials of the failed antiobesity drug rimonabant. 44 Rimonabant is a CB1 receptor antagonist developed as an anorectic agent.…”

“…Though preclinical studies do suggest relationships between mood, CB receptor density, and endocannabinoid levels, it is hard to draw conclusions about these associations, since such studies indicate that modulation of the ECS may have either pro‐ or antidepressant effects 54 . In humans, phytocannabinoids may be used to manage depressive symptoms; however, individuals with cannabis use disorder are at greater risk for developing mood disorders such as unipolar and bipolar depression 55 . Some of the most compelling data came from clinical trials of the failed antiobesity drug rimonabant 44 .…”

Disproportionate increase in cannabis use among individuals with serious psychological distress and association with psychiatric hospitalization and outpatient service use in the National Survey on Drug Use and Health 2009-2019

“…(8,9) This relationship is less well established with more prevalent mental health conditions, but recent meta-analyses suggest that cannabis use is associated with increased risk of developing anxiety (10) and mood disorders. (11)…”